Literature DB >> 27012386

The Contemporary Role of Stereotactic Radiosurgery in the Treatment of Meningiomas.

Or Cohen-Inbar1, Cheng-Chia Lee2, Jason P Sheehan3.   

Abstract

Meningiomas are among the most common intracranial tumors in adults. The mainstay of treatment has been extirpation. Stereotactic radiosurgery (SRS) is an important option in the management of inaccessible, recurrent, or residual benign meningiomas. Image guidance and a steep dose fall off are critical features. SRS offers durable tumor control for grade I meningiomas with a low incidence of complications or neurologic deficits. Neurologic function is generally preserved or improved. Complications are relatively rare. For many, the risk to benefit ratio seems favorable compared with treatment alternatives. We present a short review of the literature on SRS for intracranial meningiomas.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cyberknife; Gamma knife; Meningioma; Novalis; Stereotactic radiosurgery; Tomotherapy; Trilogy

Mesh:

Year:  2016        PMID: 27012386     DOI: 10.1016/j.nec.2015.11.006

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  9 in total

1.  Stereotactic radiosurgery for hypervascular intracranial tumors.

Authors:  Cheng-Chia Lee; Chun-Lung Chou; Ching-Jen Chen; Huai-Che Yang; Hsiu-Mei Wu; Cheng-Ying Shiau; David Hung-Chi Pan; Wen-Yuh Chung
Journal:  J Neurooncol       Date:  2018-08-20       Impact factor: 4.130

2.  MRI radiomics in the prediction of the volumetric response in meningiomas after gamma knife radiosurgery.

Authors:  Herwin Speckter; Marko Radulovic; Kire Trivodaliev; Velicko Vranes; Johanna Joaquin; Wenceslao Hernandez; Angel Mota; Jose Bido; Giancarlo Hernandez; Diones Rivera; Luis Suazo; Santiago Valenzuela; Peter Stoeter
Journal:  J Neurooncol       Date:  2022-06-17       Impact factor: 4.506

Review 3.  Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review.

Authors:  P D Delgado-López; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2020-07-10       Impact factor: 3.405

4.  Multiplatform Radiosurgery for Intracranial Meningiomas and Dose to the Dural Tail.

Authors:  Eduardo E Lovo; Alejandra Moreira; Paula A Navarro; Kaory C Barahona; Fidel Campos; Victor Caceros; Alejandro Blanco; Julio Arguello-Méndez; Leonor Arce; William O Contreras
Journal:  Cureus       Date:  2021-01-13

5.  Meningioma Treated With Hypofractionated Stereotactic Radiotherapy Using CyberKnife®: First in the United Arab Emirates.

Authors:  Nandan M Shanbhag; Christos Antypas; Abdul K Msaddi; Sinead Catherine Murphy; Teekendra T Singh
Journal:  Cureus       Date:  2022-02-01

Review 6.  Recent advances in managing/understanding meningioma.

Authors:  Nawal Shaikh; Karan Dixit; Jeffrey Raizer
Journal:  F1000Res       Date:  2018-04-24

Review 7.  Adaptive Hybrid Surgery: Paradigm Shift for Patient-centered Neurosurgery.

Authors:  Or Cohen-Inbar; Gil E Sviri
Journal:  Rambam Maimonides Med J       Date:  2018-07-30

8.  Normofractionated stereotactic radiotherapy versus CyberKnife-based hypofractionation in skull base meningioma: a German and Italian pooled cohort analysis.

Authors:  Conti Alfredo; Senger Carolin; Acker Güliz; Kluge Anne; Pontoriero Antonio; Cacciola Alberto; Pergolizzi Stefano; Germanò Antonino; Badakhshi Harun; Kufeld Markus; Meinert Franziska; Nguyen Phuong; Loebel Franziska; Vajkoczy Peter; Budach Volker; Kaul David
Journal:  Radiat Oncol       Date:  2019-11-12       Impact factor: 3.481

9.  Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-Analysis and Practice Guideline.

Authors:  Marcello Marchetti; Arjun Sahgal; Antonio A F De Salles; Marc Levivier; Lijun Ma; Ian Paddick; Bruce E Pollock; Jean Regis; Jason Sheehan; John H Suh; Shoji Yomo; Laura Fariselli
Journal:  Neurosurgery       Date:  2020-10-15       Impact factor: 4.654

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.